LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

Home・Aandelen Lijst・Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings Inc (Class A)

Gesloten

SectorGezondheidszorg

4.36 0.23

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

4.33

Max

4.52

Belangrijke statistieken
By Trading Economics
Inkomsten	36M -3.7M
Verkoop	16M 66M
EPS	0.01
Winstmarge	-5.67
Werknemers	416
EBITDA	57M 15M

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+19.63% upside

Dividenden
By Dow Jones
Volgende Winsten	10 aug 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	225M 1.6B
Vorige openingsprijs	4.13
Vorige sluitingsprijs	4.36

Maravai LifeSciences Holdings Inc (Class A) Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

27 mei 2026, 21:33 UTC

Winsten

Correction to Salesforce 1Q Sales, Profit Rise Article

27 mei 2026, 21:00 UTC

Acquisities, Fusies, Overnames

HCA Healthcare Agrees to Buy The College of Health Care Professions

27 mei 2026, 20:18 UTC

Winsten

Salesforce 1Q Sales, Profit Rise Amid Agentforce Efforts

27 mei 2026, 23:49 UTC

Marktinformatie

Nikkei Might Decline Amid Uncertainty Over Potential U.S.-Iran Peace Deal -- Market Talk

27 mei 2026, 23:39 UTC

Marktinformatie

Congo Copper, Cobalt Mining Not yet Seen Affected by Ebola Outbreak -- Market Talk

27 mei 2026, 23:34 UTC

Marktinformatie

Infratil's Longroad Energy Considers Data-Center Strategy -- Market Talk

27 mei 2026, 23:34 UTC

Marktinformatie

Global Equities Roundup: Market Talk

27 mei 2026, 23:08 UTC

Marktinformatie

Chinese Coal-Mine Disruptions Could Be Major Supply Shock for Global Markets -- Market Talk

27 mei 2026, 22:21 UTC

Marktinformatie

Salesforce Lays Out AI Monetization Strategy -- Market Talk

27 mei 2026, 21:29 UTC

Populaire aandelen

Stocks to Watch: Marvell Technology, PDD, Zscaler -- WSJ

27 mei 2026, 21:08 UTC

Winsten

Marvell's Data-Center Boom Powers Earnings Beat. Its Stock Surges. -- Barrons.com

27 mei 2026, 21:02 UTC

Winsten

Salesforce Stock Slides on Mixed Results. CFO Touts New Pricing Model. -- Barrons.com

27 mei 2026, 20:59 UTC

Acquisities, Fusies, Overnames

What to Know About Pasqal, the Quantum Start-Up Going Public Soon -- Barrons.com

27 mei 2026, 20:55 UTC

Winsten

Snowflake Stock Jumps 34%. How Amazon and an Earnings Beat Are Fueling the Gains. -- Barrons.com

27 mei 2026, 20:50 UTC

Marktinformatie

Financial Services Roundup: Market Talk

27 mei 2026, 20:48 UTC

Winsten

Marvell's Data-Center Boom Powers Earnings Beat -- and a Big Stock Surge -- Barrons.com

27 mei 2026, 20:45 UTC

Winsten

Marvell Stock Jumps on Earnings. Data-Center Revenue Is Still Booming. -- Barrons.com

27 mei 2026, 20:34 UTC

Acquisities, Fusies, Overnames

Webster Financial Stockholders Approve Sale to Banco Santander

27 mei 2026, 20:32 UTC

Winsten

Acquisities, Fusies, Overnames

Synopsys Shares Fall Despite Earnings Beat With AI and Merger in Focus -- Barrons.com

27 mei 2026, 20:32 UTC

Acquisities, Fusies, Overnames

HCA Healthcare to Acquire The College of Health Care Professions for Undisclosed Terms >HCA

27 mei 2026, 20:32 UTC

Acquisities, Fusies, Overnames

HCA Healthcare: Eric Bing Will Continue to Lead CHCP as Chancellor and CEO >HCA

27 mei 2026, 20:30 UTC

Winsten

Snowflake Beats Expectations and Expands AWS Ties Amid Software Sector Turmoil -- Barrons.com

27 mei 2026, 20:30 UTC

Acquisities, Fusies, Overnames

HCA Healthcare Announces Agreement To Acquire The College Of Health Care Professions >HCA

27 mei 2026, 20:22 UTC

Winsten

Salesforce Stock Slides on Mixed Results -- Barrons.com

27 mei 2026, 20:16 UTC

Winsten

Salesforce Stock Slides on Mixed Results -- Barrons.com

27 mei 2026, 20:13 UTC

Winsten

Synopsys Sees 3Q Adj EPS $3.63-Adj EPS $3.69 >SNPS

27 mei 2026, 20:13 UTC

Winsten

Marvell Revenue Beats Estimates. The Stock Rises. -- Barrons.com

27 mei 2026, 20:13 UTC

Winsten

Synopsys Sees FY Adj EPS $14.72-Adj EPS $14.80 >SNPS

27 mei 2026, 20:12 UTC

Winsten

Synopsys Sees FY EPS $2.49-EPS $2.91 >SNPS

27 mei 2026, 20:12 UTC

Winsten

Synopsys Sees 3Q EPS 84c-EPS 98c >SNPS

Peer Vergelijking

Prijswijziging

Maravai LifeSciences Holdings Inc (Class A) Prognose

Koersdoel

By TipRanks

19.63% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 5.24 USD 19.63%

Hoogste 6 USD

Laagste 3.94 USD

Gebaseerd op 5 Wall Street-analisten die 12-maands prijsdoelen bieden voor Maravai LifeSciences Holdings Inc (Class A) - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

5 ratings

Buy

Hold

Sell

Gebaseerd op 5 analisten die aandelenratings hebben gegeven aan Maravai LifeSciences Holdings Inc (Class A) - Dist in de afgelopen 3 maanden.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.